Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model-Reference-Cited by-同舟云学术

Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model

Published:2024-02-21 Issue:3 Volume:44 Page:209-217
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Thaliffdeen Ryan^ORCID,Yu Anthony^ORCID,Rascati Karen^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40261-024-01345-3.pdf

Reference22 articles.

1. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61:60–8.

2. Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S, et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. 2018;21:666–75.

3. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1–18.

4. Giannouchos TV, Mitsikostas D-D, Ohsfeldt RL, Vozikis A, Koufopoulou P. Cost-effectiveness analysis of erenumab versus onabotulinumtoxina for patients with chronic migraine attacks in Greece. Clin Drug Investig. 2019;39:979–90.

5. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine;Expert Review of Neurotherapeutics;2024-09-12

2. Cost-effectiveness analysis of rimegepant for on-demand acute treatment of migraine in China;Frontiers in Neurology;2024-08-23